C Nirmala1, Kalpana S Dave, Anjana Chauhan, Ronak P Bhansali, Ruchi Arora. 1. Gujarat Cancer and Research Institute, New Civil Hospital Campus, Asarva, Ahmedabad, 380016 India ; No. 91, III Cross, New Timber Yard Layout, Telecom Colony, Bangalore, 560026 India.
Abstract
OBJECTIVES: To evaluate the clinico-pathological features, surgical procedures and postoperative treatment and their relation to survival in women with granulosa cell tumours. METHODS: Data of 37 women with granulosa cell tumours were collected and reviewed retrospectively. Mann-Whitney test, log rank test and Kaplan-Meier survival analysis were applied appropriately. RESULTS: Thirty-seven women of median age 48.6 years were diagnosed in stage Ia (45.9 %), stage Ic (27 %), stage III (16.2 %) and unstaged (10.8 %). The median follow up was 5 years. Overall survival was 93 % at 5 years. Disease-free survival at 5 years was 63 %. Tumour stage and residual disease were associated with poor prognosis (p < 0.001). Mitotic rate and tumour grade were not of prognostic significance. CONCLUSIONS: Stage of disease and residual disease are valuable prognostic factors. Prospective studies with large sample sizes and long-term follow up are needed to confirm our findings.
OBJECTIVES: To evaluate the clinico-pathological features, surgical procedures and postoperative treatment and their relation to survival in women with granulosa cell tumours. METHODS: Data of 37 women with granulosa cell tumours were collected and reviewed retrospectively. Mann-Whitney test, log rank test and Kaplan-Meier survival analysis were applied appropriately. RESULTS: Thirty-seven women of median age 48.6 years were diagnosed in stage Ia (45.9 %), stage Ic (27 %), stage III (16.2 %) and unstaged (10.8 %). The median follow up was 5 years. Overall survival was 93 % at 5 years. Disease-free survival at 5 years was 63 %. Tumour stage and residual disease were associated with poor prognosis (p < 0.001). Mitotic rate and tumour grade were not of prognostic significance. CONCLUSIONS: Stage of disease and residual disease are valuable prognostic factors. Prospective studies with large sample sizes and long-term follow up are needed to confirm our findings.
Authors: Jalid Sehouli; Frank S Drescher; Alexander Mustea; Dirk Elling; Wolfgang Friedmann; Wolfgang Kühn; Margit Nehmzow; Firu Opri; Peter Klare; Mantred Dietel; Werner Lichtenegger Journal: Anticancer Res Date: 2004 Mar-Apr Impact factor: 2.480
Authors: D T Schneider; G Calaminus; R Wessalowski; R Pathmanathan; B Selle; W Sternschulte; D Harms; U Göbel; R Wessalowksi Journal: J Clin Oncol Date: 2003-06-15 Impact factor: 44.544